annb0t
Top 20
CSL (OTC: CSLLY) announced topline Phase 3 results for garadacimab (CSL312) for hereditary angioedema (HAE). HAE is a rare genetic condition that causes painful, debilitating, unpredictable episodes of swelling of the abdomen, larynx, face, and extremities, among other body areas. The study met its primary and secondary efficacy objectives and demonstrated favorable safety and tolerability. CSL aims to begin filing with global health authorities at the end of the current fiscal year for full app...
>>> Read more: CSL Posts Encouraging Data From Garadacimab In Severe Swelling Attacks
>>> Read more: CSL Posts Encouraging Data From Garadacimab In Severe Swelling Attacks
